Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Leucovorin Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentCareOregonPolicy N/A

    Leucovorin calcium prior authorization

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs prior authorization requests for Lederle Leucovorin and leucovorin calcium. Coverage is available for qualifying oncology or hematology conditions, specified cerebral folate disorders, or members currently taking methotrexate.

    Policy Summary
    PayerCareOregon
    PolicyLeucovorin calcium prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAugust 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation showing at least one qualifying coverage pathway.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    LifetimeApproval length when criteria are met
    3Primary qualifying pathways
    2Specialized folate-disorder evidence pathways

    Coverage Criteria

    Initial coverage criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage is approved when at least one of the following criteria is met:

    ONE of the following

    • The request is for an oncology- or hematology-related condition, such as use as part of a chemotherapy regimen, for graft-versus-host disease, or for anemia.
    • BOTH of the following

      • The request is for cerebral folate deficiency (CFD) with folate receptor autoantibodies (FRAAs).
      • ONE of the following

        • Medical records, such as chart notes, confirm both cerebral folate deficiency (CFD) and folate receptor autoantibodies (FRAAs).

          CFD diagnosis typically requires spinal fluid testing showing low 5-methyltetrahydrofolate levels in cerebrospinal fluid while peripheral folate status is normal. Folate receptor autoantibody testing typically requires FRAT testing.

        • The request is from a specialist, such as a pediatric neurologist or metabolic specialist, and the clinical records document high clinical suspicion for cerebral folate deficiency (CFD).
    • The request is for cerebral folate transport deficiency (CFTD) with a confirmed variant in the folate receptor 1 (FOLR1) gene (FOLR1-CFTD).
    • The member is currently taking methotrexate.

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Lederle Leucovorin and leucovorin calcium. Approval may be granted when the request meets a qualifying oncology/hematology, folate-disorder, or methotrexate pathway.

    • Oncology or hematology-related condition, such as part of a chemotherapy regimen, graft-versus-host disease, or anemia.
    • Cerebral folate deficiency with folate receptor autoantibodies, including the required diagnostic documentation or qualifying specialist review.
    • Cerebral folate transport deficiency with a confirmed FOLR1 gene variant.
    • Member is currently taking methotrexate.
    • Approval length: lifetime, through 12/31/2039.
    Documentation Required

    Confirm Cerebral Folate Deficiency and Autoantibodies

    For requests based on cerebral folate deficiency, the medical record must confirm both cerebral folate deficiency and folate receptor autoantibodies.

    • Cerebral folate deficiency typically requires spinal-fluid testing showing low 5-methyltetrahydrofolate levels while peripheral folate status is normal.
    • Folate receptor autoantibody confirmation typically requires FRAT testing.
    Documentation Required

    Specialist Documentation

    When the required laboratory confirmation is not available, submit records from a qualifying specialist documenting high clinical suspicion for cerebral folate deficiency.

    • Examples include a pediatric neurologist or metabolic specialist.
    • Provide specialist clinical records supporting the suspected folate disorder.
    Documentation Required

    Confirm FOLR1 Variant

    For cerebral folate transport deficiency, documentation must confirm a variant in the folate receptor 1 (FOLR1) gene.

    • The qualifying indication is FOLR1-related cerebral folate transport deficiency (FOLR1-CFTD).
    • Include genetic-testing or other medical-record documentation confirming the FOLR1 variant.
    Denial Risk

    No Qualifying Indication

    Deny the request when no qualifying indication is documented under the guideline.

    • No oncology or hematology-related condition.
    • No qualifying cerebral folate deficiency with folate receptor autoantibodies.
    • No cerebral folate transport deficiency with a confirmed FOLR1 variant.
    • Member is not currently taking methotrexate.
    Denial Risk

    Insufficient Folate-Disorder Documentation

    Deny or pend the request when documentation is insufficient to establish the applicable folate-disorder indication.

    • Missing diagnosis of cerebral folate deficiency or cerebral folate transport deficiency.
    • Missing supporting evidence, such as cerebrospinal-fluid testing, FRAT testing, or confirmed FOLR1 genetic findings, when applicable.
    • Missing specialist clinical records documenting high clinical suspicion when laboratory confirmation is not provided.

    Policy Background

    This guideline applies to leucovorin calcium, also identified as Lederle Leucovorin, a folate derivative requiring prior authorization. Requests may support oncology or hematology-related care, including use as part of a chemotherapy regimen, for graft-versus-host disease, or for anemia. Coverage may also apply to specified rare folate disorders, including cerebral folate deficiency with folate receptor autoantibodies and cerebral folate transport deficiency associated with a confirmed FOLR1 gene variant, as well as for members currently taking methotrexate.

    Key Definitions

    Cerebral folate deficiency (CFD)
    DefinitionCerebral folate deficiency (CFD) is a disorder characterized by reduced folate availability in the cerebrospinal fluid.
    Cerebrospinal-fluid findingDiagnosis typically requires spinal-fluid testing showing low 5-methyltetrahydrofolate levels in the cerebrospinal fluid.
    Peripheral folate findingPeripheral folate status is typically normal.
    Folate receptor autoantibodies (FRAAs)
    DefinitionFolate receptor autoantibodies (FRAAs) are autoantibodies directed against folate receptors.
    Testing referenceFolate receptor autoantibody testing typically requires FRAT testing.
    Documentation useMedical records may confirm folate receptor autoantibodies as part of the cerebral folate deficiency documentation.
    FOLR1-CFTD
    DefinitionFOLR1-CFTD is cerebral folate transport deficiency associated with a confirmed variant in the folate receptor 1 (FOLR1) gene.
    Required confirmationA confirmed variant in the FOLR1 gene is required.
    AbbreviationCFTD means cerebral folate transport deficiency.

    Initial Therapy Criteria

    Initial Approval Criteria

    Initial approval requires one of the following qualifying pathways:

    ONE of the following

    • Oncology or hematology-related condition: The request is for an oncology or hematology-related condition.

      Examples include part of a chemotherapy regimen, graft-versus-host disease, or anemia.

    • Specified cerebral folate disorder: The request is for cerebral folate deficiency with folate receptor autoantibodies, supported by qualifying medical records or specialist documentation, or for cerebral folate transport deficiency with a confirmed variant in the FOLR1 gene.
    • Current methotrexate use: The member is currently taking methotrexate.
    Policy Summary
    PayerCareOregon
    PolicyLeucovorin calcium prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAugust 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation showing at least one qualifying coverage pathway.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationPolicy BackgroundKey DefinitionsInitial Therapy Criteria